Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginGross MarginInvested CapitalMarket CapitalizationNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Sales

Dianthus Therapeutics (DNTH) Return on Equity: 2018-2025

Historic Return on Equity for Dianthus Therapeutics (DNTH) over the last 5 years, with Sep 2025 value amounting to -0.30%.

  • Dianthus Therapeutics' Return on Equity fell 10.00% to -0.30% in Q3 2025 from the same period last year, while for Sep 2025 it was -0.30%, marking a year-over-year decrease of 10.00%. This contributed to the annual value of -0.32% for FY2024, which is 37.00% up from last year.
  • Latest data reveals that Dianthus Therapeutics reported Return on Equity of -0.30% as of Q3 2025, which was up 18.37% from -0.36% recorded in Q2 2025.
  • In the past 5 years, Dianthus Therapeutics' Return on Equity ranged from a high of 1.38% in Q4 2022 and a low of -1.28% during Q3 2022.
  • Over the past 3 years, Dianthus Therapeutics' median Return on Equity value was -0.24% (recorded in 2024), while the average stood at -0.11%.
  • Over the last 5 years, Dianthus Therapeutics' Return on Equity had its largest YoY gain of 55bps in 2023, and its largest YoY loss of 163bps in 2023.
  • Over the past 4 years, Dianthus Therapeutics' Return on Equity (Quarterly) stood at 1.38% in 2022, then crashed by 163bps to -0.25% in 2023, then grew by 1bps to -0.24% in 2024, then fell by 10bps to -0.30% in 2025.
  • Its last three reported values are -0.30% in Q3 2025, -0.36% for Q2 2025, and -0.29% during Q1 2025.